Lake Street initiated coverage of Kura Oncology with a Buy rating and $23 price target. The firm's price target is based on the market opportunity for the company's commercial asset, ziftomenib, in AML, which it expects to generate risk-adjusted worldwide sales of $1.28B in 2037, says the analyst, who sees potential for additional upside from label expansion and the company's next-generation farnesyl transferase inhibitor for the treatment of solid cancers.
